CoChat

Prediagnosis Use of Statins Associates With Increased Survival Times of Patients With Pancreatic Cancer

Open access
Hamada, Tsuyoshi, Khalaf, Natalia, Yuan, Chen, Morales-Oyarvide, Vicente, Babic, Ana, Nowak, Jonathan A., Qian, Zhi Rong, Ng, Kimmie, Rubinson, Douglas A., Kraft, Peter, Giovannucci, Edward L., Stampfer, Meir J., Fuchs, Charles S., Ogino, Shuji, Wolpin, Brian M. · 2018 · Clinical Gastroenterology and Hepatology
Cited by 25

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

BACKGROUND & AIMS Statin medications, most commonly prescribed to reduce lipid levels and prevent cardiovascular disease, may be associated with longer survival times of patients with cancer. However, the association of statins with outcomes of patients with pancreatic adenocarcinoma is not clear. METHODS We analyzed the association of statin use before a diagnosis of pancreatic cancer with survival times of 648 participants in the Nurses’ Health Study and Health Professionals Follow‐up Study who were diagnosed with pancreatic adenocarcinoma from 2000 through 2013. We estimated hazard ratios (HRs) for overall mortality using Cox proportional hazards models with adjustment for potential confounders. We assessed the temporal association between prediagnosis statin use and cancer survival by 2‐year lag periods to account for a possible latency period between statin use and cancer survival. RESULTS Regular statin use before diagnosis of pancreatic cancer was associated with modestly prolonged survival compared with nonregular use (adjusted HR, 0.82; 95% CI, 0.69–0.97; P = .02). A 1‐month longer median survival was observed in regular statin users compared with nonregular users. Regular statin use within the 2 years prior to cancer diagnosis was most strongly associated with longer survival. We observed no statistically significant effect modification by smoking status, body mass index, diabetes, or cancer stage (all Pinteraction > .53). Regular statin use before diagnosis was similarly associated with survival in the Nurses’ Health Study (HR, 0.79; 95% CI, 0.64–0.97) and Health Professionals Follow‐up Study (HR, 0.86; 95% CI, 0.63–1.15). CONCLUSIONS Regular statin use before diagnosis of pancreatic cancer was associated with modest increases in survival times in 2 large prospective cohort studies.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.cgh.2018.02.022

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Cited by

See all 25

Metadata

Authors
Hamada, T., Khalaf, N., Yuan, C., Morales-Oyarvide, V., Babic, A., Nowak, J. A., Qian, Z. R., Ng, K., Rubinson, D. A., Kraft, P., Giovannucci, E. L., Stampfer, M. J., Fuchs, C. S., Ogino, S., & Wolpin, B. M.
Venue
Clinical Gastroenterology and Hepatology
Publisher
Elsevier BV
Published
2018-08
Volume
16
Issue
8
Pages
1300-1306.e3
ISSN
1542-3565 (ISSN-L)
OpenAlex
W2789190706
Cited by
25
References
2
FWCI
1.15
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.